


TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

594.352USWO

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)  
Unknown 09/509449

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/JP99/04129	July 30, 1999	July 30, 1998
TITLE OF INVENTION		
METHOD OF MEASUREMENT OF HEPATITIS C VIRUS		
APPLICANT(S) FOR DO/EO/US		
AOYAGI, et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. [X] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.		
2. [ ] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.		
3. [X] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(l).		
4. [ ] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.		
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> <li>a. [ ] is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. [X] has been transmitted by the International Bureau.</li> <li>c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US)</li> </ul>		
6. [X] A translation of the International Application into English (35 U.S.C. 371(c)(2)).		
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> <li>a. [ ] are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. [ ] have been transmitted by the International Bureau.</li> <li>c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. [X] have not been made and will not be made.</li> </ul>		
8. [ ] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).		
9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).		
10. [ ] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11. to 16. below concern document(s) or information included:		
11. [X] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.		
12. [X] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
13. [X] A FIRST preliminary amendment. [ ] A SECOND or SUBSEQUENT preliminary amendment.		
14. [ ] A substitute specification.		
15. [ ] A change of power of attorney and/or address letter.		
16. [X] Other items or information: Computer readable form and paper copy of Sequence Listing and Statement; Receipt in the Case of Original Deposit for deposition numbers FERM BP-6002, BP-6003, BP-6004, BP-6005, BP-6006, BP-6782; Submission of Sequence Listing; Cover page of PCT application PCT/JP99/04129; Notice Informing the Applicant of the Communication of the International Application to the Designated Offices; PCT Request; Notification fo the Recording of a Change; International Search Report; 3 references		

U.S. APPLICATION NO (If known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER	
Unknown <b>09/509449</b>		PCT/JP99/04129	594.352USWO	
17. [X] The following fees are submitted:		CALCULATIONS PTO USE ONLY		
BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....		\$970.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....		\$840.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....		\$760.00		
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....		\$670.00		
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....		\$96.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$840.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	7	-20 =	X \$18.00 \$	
Independent claims	1	-3 =	X \$78.00 \$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$260.00 \$		
TOTAL OF ABOVE CALCULATIONS =		\$840.00		
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		\$		
SUBTOTAL =		\$840.00		
Processing fee of \$130.00 for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$		
TOTAL NATIONAL FEE =		\$840.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+ \$40.00		
TOTAL FEES ENCLOSED =		\$880.00		
		Amount to be: refunded	\$	
		charged	\$	
<p>a. [X] Check(s) in the amount of <u>\$840.00</u> and <u>\$40.00</u> to cover the above fees is enclosed.</p> <p>b. [ ] Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>13-2725</u>.</p>				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO Curtis B. Hamre MERCHANT & GOULD P.C. P.O. Box 2903 Minneapolis, MN 55402-0903				
 SIGNATURE Curtis B. Hamre NAME 29,165 REGISTRATION NUMBER				

09/509449

416 Rec'd PCT/PTO 28 MAR 2000  
PATENT

S/N unknown

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant:	AOYAGI, et al.	Docket No.:	594.352USWO
Serial No.:	Unknown	Filed:	concurrent herewith
Int'l Appln No.:	PCTJP9904129	Int'l Filing Date:	July 30, 1999
Title:	METHOD FOR MEASUREMENT OF HEPATITIS C VIRUS		

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EL 415888455US

Date of Deposit: March 28, 2000

I hereby certify that this correspondence is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By:   
Name: Linda McCormick

PRELIMINARY AMENDMENT

Box PCT  
Assistant Commissioner for Patents  
Washington, D. C. 20231

Dear Sir:

In connection with the above-identified application filed herewith, please enter the following preliminary amendment:

IN THE TITLE

Please delete the PCT/JP99/04129 title "METHOD FOR ASSAYING HEPATITIS C VIRUS" and insert —METHOD FOR MEASUREMENT OF HEPATITIS C VIRUS—.

IN THE SPECIFICATION

A courtesy copy of the present specification is enclosed herewith. However, the World Intellectual Property Office (WIPO) copy should be relied upon if it is already in the U.S. Patent Office.

IN THE CLAIMS

In claim 3, line 1, please delete "claim 1 or 2" and insert --claim 1--.

In claim 4, line 1, please delete "any one of claims 1 to 3" and insert --claim 1--.

In claim 5, line 1, please delete "any one of claims 1 to 3" and insert --claim 1--.

In claim 6, line 3, please delete "claims 1 to 5" and insert --claim 1--.

REMARKS

The above preliminary amendment is made to remove multiple dependencies from claims 3, 4, 5 and 6.


Applicants respectfully request that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.

If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicants' primary attorney-of record, Curtis B. Hamre (Reg. No. 29,165), at (612) 336-4722.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: March 28, 2000

By   
Curtis B. Hamre  
Reg. No. 29,165  
CBH:jjw

- 1 416 Rec'd PCT/PTO 28 MAR 2000

## DESCRIPTION

METHOD FOR MEASUREMENT OF HEPATITIS C VIRUS

## Field of the Invention

5       The present invention relates to a method for detection of the hepatitis C virus (HCV), and more specifically it relates to a method for measurement of HCV core antigen or for simultaneous measurement of HCV core antigen and HCV core antibodies. The method is  
10      particularly effective for screening of multiple blood samples and the like.

## Background Art

15      Hepatitis caused by infection with HCV (hepatitis C virus) becomes chronic with high incidence, and as the infection period is prolonged it often progresses to liver cirrhosis and hepatocellular carcinoma. However, since infection with HCV occurs mainly through blood and blood-derived components, it is possible to identify and eliminate the source of infection to block the infection route. Current methods of identifying infection sources  
20      are primarily methods of detecting antibodies against HCV polypeptides, but methods are being sought that can identify infection sources with greater accuracy.

25      Such methods are being sought because of the existence of a period of time known as the "window period" after HCV infection during which the antigen is present but antibodies are not yet produced. Antibody testing cannot determine whether serum taken during this period is infected or not. Therefore, there is a risk of secondary infection by the blood derived components, such as blood donation, blood components, factors from blood, contaminated specimens in the window period, because blood donor is screened by the antibody test that can not exclude such specimens. For this reason it has been  
30      necessary to detect HCV itself, that is, HCV particles, instead of antibodies against HCV polypeptides to reduce the risk.  
35

Detection and measurement of HCV itself is possible by detecting antigens or genome (RNA) in the HCV particles. Here, an antigen in the HCV particles could be core antigen or an envelope antigen (E1, E2).

5 A lot of variants were reported in the antigenic region of envelope protein such as hyper variable region. In addition, heterogeneities of sequences between genotypes were reported. In order to detect all of these variants and heterogeneous sequences, it is necessary to  
10 use probes that bind to several regions respectively.

15 Here, "probe" will be used to refer to a molecule that binds specifically to an antigen, for example a molecule which recognizes and binds to an antigen molecule, such as a receptor, antibody, recombinant antibody, functional molecule or functional structure.

The amino acid sequences of core antigen were more conserved than those of envelope antigens. By selecting well conserved regions among several HCV genotypes, a probe recognizing core antigen of all genotype could be  
20 obtained. Consequently, the method whose results should not be affected by genotypes will be constructed.

25 However, one point must be considered in constructing systems for detection of antigens. Specifically, it is highly possible that antibodies in specimens from the subject compete with the antigen-detecting probe for the binding sites, resulting in lowering the detection of sensitivity for the antigen by interfering probe binding. A method would be constructed by using probes recognizing the regions that could not be  
30 bound or interfered by antibodies in the specimens. However, it is difficult to prepare probes that fulfill these conditions for molecules reported to have multiple antibody-binding sites, such as HCV core antigen.

35 Thus, detection of antigen molecules requires elimination of antibodies that inhibit probe binding. Methods of elimination include methods of elimination based on physical principles, for example methods

032264-Subpoena

utilizing differences in molecular weight for separation and fractionation of HCV particles and antibodies. Examples of such methods include gel filtration, ultracentrifugation, density gradient centrifugation and 5 molecular weight fractionation using membranes such as ultrafiltration membranes. However, since antibodies often form complexes with other biomolecules whereby they become high molecular weight entities, their separation from HCV particles is difficult by methods based on 10 physical principles. These methods also employ special equipment during the processing steps, which makes their application difficult for mass screening, such as blood screening.

HCV particles are preferentially precipitated by the 15 difference of their solubility in water-based solution containing PEG (polyethylene glycol), which alter the microenvironment of water. However, it will be very difficult to separate antibodies and their complex with antigens from HCV particles, because these components 20 precipitated in same fractions. Moreover, HCV particles often form immune complexes between the antigens in the HCV particles and antibodies that recognize them, and it is difficult to separate only the antibodies or antigens from the immune complexes.

The methods implemented are therefore ones whereby 25 substances (antibodies, etc.) that inhibit probe functions are eliminated by destroying their functions. One such method for losing antibody functions is a method in which the antibody protein is denatured by exposure to 30 conditions that denature the protein structure, but it is essential here to destroy the function of the antibody while not eliminating the function of the object antigen, i.e. the function of binding with the probe, which means not losing the epitope or allowing the epitope to be 35 displayed again, if the probe is an antibody.

The target function of a method of determining the HCV infection will differ depending on the goal.

Antibody testing is a method only to determine the specimen containing antibodies against HCV. When antibodies against HCV are present in a specimen, there are cases where the specimen donor is currently contains  
5 HCV because of active injection of HCV, while there are other cases where the specimen does not contain HCV because of HCV elimination from body by treatment or material recovery it is difficult to discriminate these therefore cases based on the presence or absence of  
10 antibodies.

The important function of antigen test is to determine whether or not HCV is present in a specimen or to indicate the level of HCV when it is present. It is not dependent on the question of whether or not  
15 antibodies are present.

For treatment, HCV antibody testing provides important information for determining whether HCV is the main cause of hepatitis. However, the test for HCV itself is require for definite diagnosis. Determining  
20 whether HCV has been eliminated from the body is important in judging the efficacy of treatment. The information of the level of antigen is essential in making a such decision for treatment. That is, for treatment it is important to know whether or not and at  
25 what level the antigen is present, regardless of the presence or absence of antibodies. For treatment, then, the most important testing methods are those which indicate the presence or absence and the level of antigen.

30 For blood and blood-derived components, preventing secondary infection is of greatest importance. For this purpose, testing methods that assess the risk of HCV infection. Antibody testing is currently being used as the primary testing method in this field.

35 However, as explained above, antibody testing cannot determine whether serum is infected during the window period after HCV infection. Consequently, when blood-

derived substances such as transfusion and blood components, blood preparations, etc. are utilized for screening by antibody testing, there is a risk of secondary infection by specimens in the window period.

5        Coupling this with antigen testing is desired in order to reduce this risk, but antigen testing is still not implemented for mass screening for blood donation.

If a testing method existed that could determine the presence or absence of antigen with a theoretical 10 accuracy (sensitivity, specificity) of 100%, that method could be used as the sole testing method. However any method have a limit of the detection sensitivity and cannot measure levels below that detection sensitivity. Thus, no testing method exists that can discriminate with 15 100% accuracy. There remains the possibility of missing the source of infection by antigen testing alone, and it is for this reason that measurement of both antibody and antigen is necessary to reduce the risk of secondary infection. If the antigen test, having high sensitivity 20 and specificity sufficient for mass screening, is available, both antigen and antibody test were required for the screening. This requirement will result in higher cost of the screening, because the number of tests performed with samples should increase than present.

25       It is therefore clear that if measurement of antigen and antibody by the same method becomes possible, it will allow a reduction in the number of tests performed in the field, thus providing a major effect.

As already mentioned, despite the development of 30 antibody detecting methods and antigen detecting methods, when it is attempted to detect antigen under conditions for detecting antibodies as alluded to above, the antigen cannot be efficiently detected because of the presence of antibodies which inhibit binding of probes that detect 35 the antigen. Even under conditions for detection of antigen, however, the adopted methods eliminate antibodies that compete against detection of antigen, as

explained above, and therefore antibodies cannot be detected. The currently reported methods, therefore, do not allow detection of antigen and antibody by a single method.

5            Disclosure of the Invention

For the purpose of reducing secondary infection when utilizing blood and materials derived from blood, it is not necessary to distinguish between infected persons and formerly infected persons, as it is sufficient to be able 10 to determine whether or not antibody or antigen is present. The present invention therefore provides a method of detecting antigen in specimens during periods in which they contain no antibodies, such as during window periods, and detecting the antigen or the antigen 15 and antibodies in specimens during periods in which the antibodies are present; it therefore provides a new testing method which is desirable for testing of blood and blood-derived substances.

In order to solve the problems mentioned above, the 20 present invention provides a method for measurement of the hepatitis C virus (HCV), characterized by measuring HCV core antigen by its binding with one or more probes in the presence of one or more detergents with one or more alkyl chains and one or more secondary to quaternary 25 amines or one or more non-ionic detergents, or both.

The present invention further provides a method for measurement of HCV core antigen by the aforementioned method while also measuring HCV core antibody by its binding with a probe.

30            BRIEF EXPLANATION OF DRAWINGS

Fig. 1 is a graph showing a comparison of antibody titer of monoclonal antibody C11-15 with antibody titers of other monoclonal antibodies C11-3, C11-7, C11-10 and C11-14.

35            Fig. 2 is a graph showing a result of ELISA for measuring HCV-RNA positive specimen using as primary antigen immobilized on a solid phase each of various

monoclonal antibodies alone, or mixture thereof.

Embodiments for Carrying out the Invention

The method of detecting HCV infection provided by the present invention is a method whereby the antigen is detected in a specimen during a period in which no antibodies are present, such as during a window period, and whereby the antigen or both the antibody and antigen are detected during periods in which antibodies are present. In other words, during window periods in which no antibodies are present, the fact that no antibodies are present means that there is no need to eliminate antibodies during detection of the antigen.

Consequently, pre-processing for detection of the antigen is no longer necessary.

Nevertheless, the regions on the antigen, that are recognized by the probe, must be displayed for detection, because the core antigens are packaged into virus particle. HCV particles are believed to have a structure wherein complexes are formed between the genomic RNA and the core antigen, forming particles which are coated with lipid outer membranes comprising envelope proteins. They are also believed to exist in the blood in the form of complexes with low density lipoproteins (LDLs) and/or anti-HCV antibodies. The probe cannot recognize and bind with the core antigen when it is in the viral particles present in the blood. Thus, detection of core antigen requires processing to remove the structure enveloping the core antigen to allow recognition of the core antigen by the probe.

The present invention therefore further provides a reaction method comprising reaction conditions and a reaction system by which core antigen in HCV particles contained in a specimen is displayed so that it can be recognized by a probe for recognition of the core antigen, as well as a reagent that includes such a reaction system.

During periods in which antibodies are present at a

sufficient level, antibodies against the core antigen  
that compete for the binding site of the probe are  
sometimes present in the specimen, and this can lower the  
detection sensitivity for the core antigen. Also, when  
5 the core antigen is exposed to allow the probe to bind in  
the presence of the antibodies to compete with the probe  
for the binding, the levels of antibodies that bind the  
antigen for the antibody test will be reduced by their  
absorption to the displayed core antigen of the virus  
10 particles. As a result, the sensitivity of the antibody  
test, which measure the amount of immuno-complex of  
antibodies with the antigens for the antibody test.

Consequently, while the antigen used for detection  
of HCV antibodies may be one consisting solely of the  
core antigen epitope, it is preferably a peptide or  
15 polypeptide including an HCV epitope other than the core  
antigen. It may also be a peptide or polypeptide, or  
compound, other than the peptide or polypeptide including  
the HCV epitope, which mimics the HCV epitope.

20 However, the probe used for detection of the core  
antigen and the HCV epitope or the compound substituting  
for the HCV epitope are preferably not entities that bind  
through mutual recognition.

The antibody used as the probe for the HCV core  
25 antigen or the labeled antibody for detection of the HCV  
core antigen may be a polyclonal antibody obtained by  
immunization of an experimental animal such as a mouse,  
rabbit, chicken, goat, sheep, cow, etc.; a monoclonal  
antibody produced by a hybridoma obtained by separating  
30 spleen cells from an immunized individual and fusing them  
with myeloma cells; a monoclonal antibody produced by  
spleen cells or blood leukocytes that have been  
immortalized with the EB virus; or a monoclonal antibody  
produced by a human or chimpanzee infected with HCV; a  
35 recombinant antibody produced by cells transformed by a  
recombinant antibody gene constructed by combining an  
immunoglobulin constant region gene fragment with a

variable region gene fragment obtained from immunoglobulin cDNA or chromosomal DNA from a mouse, human, etc., a variable region gene fragment constructed by combining a portion of immunoglobulin cDNA or  
5 chromosomal DNA with an artificially created sequence, a variable region gene fragment constructed using an artificial gene sequence or a variable region gene fragment created by a gene recombination method using these as materials; a phage antibody created by fusing  
10 any of the aforementioned variable region gene fragments with the structural protein of a bacteriophage, for example; or a recombinant antibody produced by cells transformed by a recombinant antibody gene constructed by combining any of the aforementioned variable region gene  
15 fragments with another appropriate gene fragment, such as a portion of the myc gene.

Probes produced by artificial introduction of variable regions into trypsin molecules, probes obtained by artificially modifying molecules that bind  
20 specifically to proteins such as receptors, and other probes prepared by combinatorial chemistry techniques, may be used so long as they exhibit high specificity and affinity for the core antigen.

The above-mentioned monoclonal antibodies can be  
25 easily prepared by those skilled in the art. Preparation of monoclonal antibodies from hybridomas is well-known. An example thereof is periodic immunization of BALB/c mice or the like either intraperitoneally or  
30 intradermally using the fused polypeptide or polypeptide (hereunder referred to as "the present antigen") as an antigen either alone or bound to BSA, KLH or the like, in simple form or in admixture with an adjuvant such as Freund's complete adjuvant. The present antigen is administered through the caudal vein as a booster  
35 immunization once the blood antibody titer has increased, and after antiseptic extraction of the spleen, cell fusion is carried out with an appropriate mouse myeloma

cell line to obtain hybridomas. This method can be carried out according to the method of Kohler and Milstein (Nature 256: 495-497, 1975).

The hybridoma cell lines obtained by the above procedure are cultured in a suitable culture solution, and then a hybridoma cell line producing antibodies that exhibit specific reaction with the present antigen is selected and cloned. The cloning of the antibody-producing hybridoma may be accomplished by the limiting dilution method, or the soft agar method (Eur. J. Immunol. 6: 511-519, 1976). The monoclonal antibody produced is purified by a method such as column chromatography using Protein A, etc.

A molecule to be used as a probe may be prepared instead of the aforementioned monoclonal antibody. For example, recombinant antibodies are discussed in detail in a general outline by Hoogenboon (Trends in Biotechnology, 15: 62-70, 1997).

According to the invention, the antigen used as a probe for HCV core antibodies in a specimen or the antigen used for production of the HCV core antibodies is, specifically, a polypeptide having an amino acid sequence represented for example by SEQ.ID. No.1 or No.2, or a fused polypeptide including one of the amino acid sequences listed as SEQ.ID. Nos.3 to 6, and these can be obtained by recombinant expression of DNA coding therefor.

The principle for detection in this case may be a method commonly used for immunoassay, such as the enzyme-labeled antibody method, fluorescent labeling method, radioisotope labeling method, etc., and the principle for enzyme detection in the enzyme-labeled antibody method is the colorimetric method, fluorescent method, chemiluminescence method, etc. The method used for detection of the antibody may be one which is commonly employed for antibody detection, such as the double-antigen sandwich method, and a one-step sandwich system

may likewise be used for detection of the antigen as well.

One mode of the invention is the reaction system described below. (1) A probe for the HCV core antigen, for example antibodies for the HCV core antigen, and (2) a compound comprising the HCV epitopes, for example a peptides, peptide compounds or polypeptides comprising the HCV epitopes, or a mixture thereof, are immobilized on a carrier used for immunoassay, such as a microtiter plate. In order to capture core antigens and HCV antibodies in the specimen, the immobilized carrier is reacted with the specimens in the solution that contains the compounds to expose the core antigen in the virus particles or complexes with the particles and not to inhibit the function of HCV antibodies for binding to the HCV epitopes.

After then removing the unbound components in the specimen by, for example, washing the carrier with a suitable buffer solution, it is reacted with a reaction solution containing probes that recognizes the core antigen bound to the carrier, for example an enzyme-labeled antibodies for the core antigen, and probes that recognizes an antibody for the HCV epitope bound to the carrier, for example an enzyme-labeled anti-human antibody mouse monoclonal antibody, to cause specific binding with the core antigen and the antibodies to the HCV epitopes captured the carrier. After the reaction, the carrier is washed with a suitable buffer solution to remove the unreacted components, and detection of the label by an appropriate method will allow detection of the core antigen and the antibodies to the HCV epitope, which are present in the specimen.

It will be readily apparent to researchers in the relevant field that this may be applied as well to B/F separation methods that can be used for common immunoassay methods, such as immunochromatography.

Reaction conditions suitable for antigen detection

The reaction system suitable for antigen detection in the system provided by the present invention is a system under mild conditions which will not destroy the function of the antibody to the HCV epitopes, while also being under conditions that will sufficiently expose the region recognized by the antibody probe which is to recognize the HCV antigen amidst the HCV particles that are exist as a complex structure in the specimen.

It has been demonstrated that core antigen can be detected if the viral particles that have been separated by ultracentrifugation (Takahashi et al., 1996, J. Gen. Virol., 73:667-672) or HCV particles which have been aggregated and precipitated with polyethylene glycol are treated with a non-ionic detergent such as Tween80 or Triton X100 (Kashiwakuma et al., 1996, J. Immunological Methods 190:79-89); in the former case, however, the detection sensitivity is insufficient and it is doubtful whether sufficient antigen is exposed. In the latter case, treatment agents other than detergents were added to inactivate the antibodies. In addition nothing is mentioned about the actual effect of the detergent.

For the present invention, the conditions were first studied on the basis of the detergent, and by preparing reaction solutions with detergent-based compositions, and it has become possible to efficiently detect antigen in HCV particles by simply diluting the specimen with the reaction solution without applying pre-processing involving procedures such as centrifugation and heating as in hitherto reported HCV antigen detection systems.

In order to construct the system which this invention provide, it is necessary to effectively extract the core antigen from the viral particles, suppress interaction between the various substances in the serum, and provide conditions which allow efficient reaction between the probe and the antigen. As detergents which are effective for this purpose there may be mentioned

detergents with alkyl groups and secondary to quaternary amines in the same molecule, and non-ionic detergents.

In a detergents comprising with alkyl chains and secondary to quaternary amines, the alkyl chain is preferably a linear alkyl chain, with the number of carbon atoms being preferably 10 or greater and more preferably 12-16. The amine is preferably a tertiary amine or quaternary amine (ammonium). As specific detergents there may be mentioned dodecyl-N-sarcosinic acid, dodecyltrimethylammonium salts, cetyltrimethylammonium salts, 3-(dodecyldimethylammonio)-1-propanesulfonic acid, 3-(tetradecyldimethylammonio)-1-propanesulfonic acid, dodecylpyrimidium salts, cetylpyrimidium salts, decanoyle-N-methylglucamide (MEGA-10), dodecyl-N-betaine, and the like. Dodecyl-N-sarcosinic acid and dodecyltrimethylammonium salts are preferred.

The aforementioned non-ionic detergent is preferably one with a hydrophilic-lipophilic balance of 12 to 14, with polyoxyethylene isoctyl phenyl ethers such as Triton X100, Triton X114, etc. and polyoxyethylene nonyl phenyl ethers such as Nonidet P40, Triton N101, Nikkol NP, etc. being preferred.

According to the invention the above-mentioned two types of detergents may be used alone, but their combinations are more preferable since synergistic effects can be achieved.

The present inventors found that a carrier, which was immobilized antigens containing HCV epitopes for detection of HCV antibodies and antibodies to HCV antigens for the detection of HCV antigen, is able to efficiently capture HCV antigen, HCV antibodies in the specimens without HCV antibodies, or HCV antigen, respectively. The inventors also found that the carrier efficiently capture both HCV antigens and antibodies in the specimens containing HCV antigens and antibodies, and gave higher signals derived by their binding. Based upon

these findings, the inventors have completed the present invention.

A method for simultaneously detecting an viral antigen and antibodies to virus related portion has been already reported for HIV (Weber et al., J. Clinic.

Microbiol., 36: 2235-2239, 1998). In the case of HIV, it is effective to detect p24 which is gag protein for a viral antigen test. On the other hand, for test for an antibody against viral antigen, it is effective to detect antibodies against envelop protein and p19 which is a gag protein. Therefore, a method for simultaneously detecting a viral antigen and an antibody against viral antigen is established by combining an antigen test which detects g24 that is a gag protein, and an antibody test which detects antibodies against envelop protein and p19 that is a part of gag protein.

In such a case wherein epitopes used for detection of viral antigens is different from epitopes recognized by antibodies in a specimen used for detection of viral antibodies, it is relatively easy to construct a method for simultaneously detecting viral antigens and an antibodies against viral antigens. This is because, for example, in the case of HIV test, the antigen p24 recognized by a probe for detection of the antigen, for example, a monoclonal antibody against HIV epitope, and antigens recognized by antibodies contained in a specimen from a patient, which are envelop protein and p19 that is a part of the gag protein are different proteins, and therefore the probe used for the antigen test cannot recognize the envelop protein and the p19 which is a part of the gag protein. Accordingly, there is no interference between the antigen detection system and the antibody detection system, for example a non-specific reaction, decrease in sensitivity caused by competitive reaction between the probe and HIV epitope used for antibody detection.

However, for detection of antibodies against HCV

epitopes, the detection of antibodies against core antigen is highly useful from a clinical point of view (Chiba et al., Proc. Natl. Acad. Sci. USA 88: 4641-4645, 1991; Bresters et al., Vox Sang, 62: 213-217, 1992).

5 Therefore, it is essential for the antibody detection to detect an antibodies against the core antigen epitopes. On the other hand, for the antigen detection, detection of the core antigen is most useful in detection of HCV antigens, because, of antigens which form viral  
10 particles, the mutation rate of the core antigen is lower than that of other antigens such as E1 and E2. Namely, to construct an assay system which simultaneously detects HCV antigen and HCV antibodies, the same antigen, i.e., the core antigen must be used for both the antigen  
15 detection system and the antibody detection system.

Therefore, if the core antigen is used without any improvement, the following problems are caused: a monoclonal antibody against the core antigen used for the detection of antigen binds to the core antigen used for the  
20 detection of antibody, resulting in decrease in sensitivity for detection of core antigen in a specimen; the monoclonal antibody binds to the antigen used for the detections of antibody resulting in nonspecific reaction in the antigen test; and the HCV epitope for the antibody  
25 test is masked resulting in decrease in sensitivity.

To solve the above-mentioned problems, the present inventors found that both the antigen and antibodies can be efficiently detected simultaneously by distinguishing the epitopes recognized by monoclonal antibody in the  
30 antigen detection from the epitopes of the core antigen for antibodies present in the specimen, and completed the present invention.

An combination of epitopes suitable for simultaneous detection of the antigen and antibodies is shown in  
35 detail in Examples described hereinafter.

Regarding the epitopes for antibodies in a specimen against the core antigen, various epitope analyses show

that the most important regions are present at the N-terminal region of the core antigen, especially from the position 1 to the position 40 of the HCV polypeptide (Okamoto et al., Hepatology 15: 180-186, 1992; Sallsberg et al. J. Clinical. Microbiol., 30: 1989-1994, 1992; Sallsberg et al., J. Med. Vilol. 43: 62-68, 1994). In addition, an epitope which genotype-specifically reacts is present in the region from the position 60 to the position 80 of the HCV polypeptide (Machida, Hepatology, 16: 886-891, 1992; Japanese Patent Application 9-209522). Therefore, it is important that an antigen for detection of antibodies against the HCV epitopes has a sequence from the position 1 to the position 40 and from the position 66 to the position 80 of the HCV polypeptide.

Accordingly, Example discloses an antigen polypeptide "CEPM" having the sequence from the position 1 to the position 42 and from the position 66 to the position 80 of the HCV polypeptide as an antigen for detection of HCV antibodies. Note that the CEPM is an antigen having an artificial sequence comprising the following regions of the HCV polypeptide in the described order, and a process for construction thereof is described in Japanese Patent Application No. 9-209522. The sequence thereof is described in SEQ ID NO:10.

The linkage of the HCV epitopes of CEPM:  
(1238-1312)-(1363-1460)-(1712-1751)-(66-80)-  
(1686-1704)-(1716-1751)-(66-80)-(1690-1713)-  
(1-42)

On the other hand, for the detection of antigen, monoclonal antibodies recognizing and binding to the region from the position 100 to the position 130 of the HCV polypeptide, antibodies against which region are relatively rare in specimens, is used as a primary antibody, and to detect the core antigen captured by the primary antibody, a monoclonal antibody recognizing a region from the position 40 to the position 50 of the HCV polypeptide, which region is not used for the detection

of antibody, is used as a secondary antibody.

Both the above-mentioned monoclonal antibodies do not bind to the antigenic region from the position 1 to the position 42 of the HCV polypeptide, which is used for the detection of HCV antibodies, and therefore by using the above-mentioned antibodies and antigen, no reaction interference occurs in the antigen detection system and the antibody detection system, and both the detection systems can simultaneously function.

10 Examples

The invention will now be explained in detail by way of the following examples.

Example 1. Expression of HCV-derived polypeptide and purification

15 (A) Construction of expression plasmid

An expression plasmid corresponding to the HCV core region was constructed in the following manner. One microgram each of DNA of plasmids pUC·C11-C21 and pUC·C10-E12 obtained by incorporating clone C11-C21 and clone C10-E12 (Japanese Unexamined Patent Publication No. 6-38765) into plasmid pUC119 were digested at 37°C for one hour with 20 µl of a restriction enzyme reaction solution [50 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 1 mM DTT, 100 mM NaCl, 15 units of EcoRI and 15 units of Clal enzyme] and [10 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 1 mM DTT, 50 mM NaCl, 15 units of Clal and 15 units of KpnI], respectively, and this was followed by electrophoresis on 0.8% agarose gel to purify an approximately 380 bp EcoRI-Clal fragment and an approximately 920 bp Clal-Kpni fragment.

To these DNA fragments and a vector obtained by digesting pUC119 with EcoRI and Kpni there were added 5 µl of a 10 x ligase buffer solution [660 mM Tris-HCl (pH 7.5), 66 mM MgCl<sub>2</sub>, 100 mM dithiothreitol, 1 mM ATP], 1 µl of T4 ligase (350 units/µl) and water to 50 µl, and this was followed by overnight incubation at 16°C for ligation reaction. The plasmid was used to transform *E. coli*

JM109, obtaining plasmid pUC·C21-E12.

A 1 ng portion of DNA of this plasmid pUC·C21-E12 was subjected to PCR using two primers (5'-GAATT CATGGCACGAATCCTAAA-3' (SEQ.ID. No.7), and 5'-TTAGTCCTCCAGAACCCGGAC-3' (SEQ.ID. No.8)). The PCR was conducted using a GeneAmpTM Kit (DNA Amplification Reagent Kit, product of Perkin Elmer Cetus) under conditions of DNA denaturation at 95°C for 1.5 minutes, annealing at 50°C for 2 minutes and DNA synthesis at 70°C for 3 minutes, and the resulting DNA fragment was separated by 0.8% agarose gel electrophoresis and purified by the glass powder method (Gene Clean).

Separately, pUC19 was digested with restriction enzyme SmaI, and the DNA fragment obtained by PCR was added to 5 µl of a 10 x ligase buffer solution [660 mM Tris-HCl (pH 7.5), 66 mM MgCl<sub>2</sub>, 100 mM dithiothreitol, 1 mM ATP] and 1 µl of T4 ligase (350 units/µl) with water to 50 µl, after which overnight incubation was performed at 16°C for ligation reaction. The plasmid was used to transform *E. coli* JM109, obtaining plasmid pUC19·C21-E12·SmaI.

One microgram of this plasmid DNA was digested at 37°C for one hour with 20 µl of a restriction enzyme reaction solution [150 mM NaCl, 6 mM Tris-HCl (pH 7.5), 6 mM MgCl<sub>2</sub>, 15 units of EcoRI and 15 units of BamHI enzyme], and this was followed by 0.8% agarose gel electrophoresis to separate an approximately 490 bp EcoRI-BamHI fragment, which was then purified by the glass powder method.

A 1 µg portion of DNA of the expression vector Trp·TrpE (Japanese Unexamined Patent Publication No. 5-84085) was then digested at 37°C for one hour with 20 µl of a restriction enzyme reaction solution [150 mM NaCl, 6 mM Tris-HCl (pH 7.5), 6 mM MgCl<sub>2</sub>, 15 units of EcoRI and 15 units of BamHI enzyme], and after adding 39 µl of water to the reaction solution and heating it at 70°C for 5 minutes, 1 µl of bacterial alkali phosphatase (BAP)

(250 units/ $\mu$ l) was added prior to incubation at 37°C for one hour.

5 Phenol was added to the reaction solution for phenol extraction, and DNA in the resulting aqueous layer was  
precipitated with ethanol and dried. A 1  $\mu$ g portion of  
the obtained EcoRI-BamHI treated vector DNA and the  
aforementioned core fragment were added to 5  $\mu$ l of a 10 x  
ligase buffer solution [660 mM Tris-HCl (pH 7.5), 66 mM  
MgCl<sub>2</sub>, 100 mM dithiothreitol, 1 mM ATP] and 1  $\mu$ l of T4  
10 ligase (350 units/ $\mu$ l) with water to 50  $\mu$ l, and this was  
followed by overnight incubation at 16°C for ligation  
reaction.

15 A 10  $\mu$ l portion of this reaction solution was used  
to transform *E. coli* HB101. A competent *E. coli* strain  
for the transformation can be prepared by the calcium  
chloride method [Mandel, M. and Higa, A., J. Mol. Biol.,  
53, 159-162 (1970)]. The transformed *E. coli* was  
spreaded onto an LB plate (1% tryptone, 0.5% NaCl, 1.5%  
20 agar) containing 25  $\mu$ g/ml of ampicillin, and was  
incubated overnight at 37°C. One loopful of colonies  
formed on the plate was taken and transferred to LB  
medium containing 25  $\mu$ g/ml of ampicillin for culturing  
overnight at 37°C.

25 After centrifuging 1.5 ml of the cell culture  
solution and collecting the cells, mini-preparation of  
the plasmid DNA was carried out by the alkali method  
[Manniatis et al., Molecular Cloning: A Laboratory  
Manual, 1982)]. A 1  $\mu$ g portion of the obtained plasmid  
DNA was digested at 37°C for one hour with 20  $\mu$ l of a  
30 restriction enzyme reaction solution [150 mM NaCl, 6 mM  
Tris-HCl (pH 7.5), 6 mM MgCl<sub>2</sub>, 15 units of EcoRI and 15  
units of BamHI enzyme] and subjected to agarose gel  
electrophoresis, and a Trp-TrpE core 160 expression  
plasmid producing an approximately 490 bp EcoRI-BamHI  
35 fragment was selected.

(B) Expression and purification of polypeptide encoded by clone core 160

*E. coli* HB101 bearing expression plasmid Trp·TrpE core 160 was inoculated in 3 ml of 2YT medium (1.6% tryptone, 1% yeast extract, 0.5% NaCl) containing 50 µg/ml of ampicillin, and cultured at 37°C for 9 hours. One milliliter of the culture solution was subcultured at 37°C in 100 ml of M9-CA medium (0.6% Na<sub>2</sub>HPO<sub>4</sub>, 0.5% KH<sub>2</sub>PO<sub>4</sub>, 0.5% NaCl, 0.1% NH<sub>4</sub>Cl, 0.1 mM CaCl<sub>2</sub>, 2 mM MgSO<sub>4</sub>, 0.5% casamino acid, 0.2% glucose) containing 50 µg/ml of ampicillin. Indoleacrylic acid was added to a final concentration of 40 mg/l at the point when OD<sub>600</sub> = 0.3, and culturing was continued for 16 hours. The culture solution was subjected to centrifugation separation to collect the cells.

The cells were suspended by addition of 20 ml of buffer solution A [50 mM Tris-HCl (pH 8.0), 1 mM EDTA, 30 mM NaCl], and further centrifugation yielded 2.6 g of cells. These obtained cells were suspended in 10 ml of buffer solution A, and after disrupting the *E. coli* membranes by ultrasonic disruption they were centrifuged to obtain an insoluble fraction containing a fused polypeptide of the polypeptide encoded by HCV cDNA and TrpE. To this fraction there was added 10 ml of buffer solution A containing 6 M urea for solubilization and extraction of the fused polypeptide. The solubilized extract was subjected to ion-exchange column chromatography using S-Sepharose for purification of the fused polypeptide.

30

Example 2. Hybridoma construction method

The fused polypeptide (TrpC11) prepared by the method described above was dissolved in 6 M urea and then diluted in a 10 mM phosphate buffer solution (pH 7.3) containing 0.15 M NaCl to a final concentration of 1.0 mg/ml and mixed with an equal amount of TiterMax to make a TrpC11 suspension. The suspension was adjusted to a

TrpC11 concentration of 0.01 to 0.05 mg/ml and used for intraperitoneal injection into 4- to 6-week-old BALB/c mice. After approximately 8 weeks the immunized animals were further injected through the caudal vein with a physiological saline solution prepared to a TrpC11 concentration of 0.005 to 0.03 mg/ml.

On the third day after the final booster immunization, the spleens of the immunized animals were aseptically extracted, sliced with scissors, broken into individual spleen cells using a mesh, and washed 3 times with RPMI-1640 medium. A logarithmic growth stage mouse myeloma cell line PA1 which had been cultured for a few days in the presence of 8-azaguanidine and had the revertants completely removed was washed in the same manner described above, after which  $1.8 \times 10^7$  of these cells and  $1.0 \times 10^8$  of the spleen cells were placed in a 50-ml volume centrifuging tube and mixed. This was subjected to centrifugal separation at  $200 \times g$  for 5 minutes, the supernatant was removed off, and 1 ml of RPMI-1640 medium containing 50% polyethylene glycol (PEG) 4000 (product of Merck Co.) heated at  $37^\circ C$  was added for cell fusion.

After removing the PEG from the fused cells by centrifugation ( $200 \times g$ , 5 minutes), a 96-well plate was used for culturing for 1 to 2 weeks in RPMI-1640 medium containing hypoxanthine, aminopterin and thymidine (hereunder abbreviated to "HAT"), to allow growth of only the hybridomas. They were then grown in HAT-free medium, and after about 2 weeks the ELISA method was used to search for clones producing the target antibody, upon which hybridomas were obtained which produced the monoclonal antibody of the invention having the desired reaction specificity.

A conventional limiting dilution procedure was followed to search for and monoclonal the target antibody-producing strains among the obtained hybridomas, and the hybridomas were designated as HC11-14, HC11-10, HC11-3

and HC11-7. These four different hybridomas were deposited at the National Institute of Bioscience and Human Technology on July 4, 1997 as FERM BP-6006, FERM BP-6004, FERM BP-6002 and FERM BP-6003.

5

Example 3. Preparation of monoclonal antibody

The hybridomas obtained by the method described in Example 2 were transplanted into mice abdomens treated with pristane, etc., and the monoclonal antibodies that were gradually produced in the ascites were collected. 10 The monoclonal antibodies were purified by separating the IgG fraction with a Protein A bound Sepharose column.

The isotype of the monoclonal antibodies produced by the above-mentioned four different hybridomas, C11-14, 15 C11-10, C11-7 and C11-3, were identified by the double immunodiffusion method using each isotype antibody of rabbit anti-mouse IG (product of Zymed Co.), and it was found that C11-10 and C11-7 were IgG2a, and C11-14 and C11-3 were IgG1. As a result of epitope analysis of 20 these four monoclonal antibodies using 20 peptides synthesized by HCV/core region-derived sequences, they were shown to be monoclonal antibodies which specifically recognize portions of the core sequence as shown in Table 1.

25

Table 1

Antibody	Recognition site
C11-14	<sup>41</sup> Gly- <sup>50</sup> Arg (SEQ.ID. No.4)
C11-10	<sup>21</sup> Asp- <sup>40</sup> Arg (SEQ.ID. No.3)
C11-3	<sup>100</sup> Pro- <sup>120</sup> Gly (SEQ.ID. No.5)
C11-7	<sup>111</sup> Asp- <sup>130</sup> Phe (SEQ.ID. No.6)

Example 4. Method for efficient detection of antigen without pre-processing procedure

A specimen containing HCV particles was diluted in a containing detergents reaction solution to determine the efficiency with which HCV core antigen was detected.

30

The detection of the HCV core antigen was performed by the sandwich enzyme immunoassay (EIA) using monoclonal antibodies for the HCV core antigen. Of the monoclonal antibodies obtained in Example 3, C11-3 and C11-7 were used as antibodies for capturing the core antigen, and C11-10 and C11-14 were used as antibodies for detection of the captured core antigen.

The EIA was performed basically under the following conditions. Solutions of monoclonal antibodies C11-3 and C11-7 in acetate buffer solutions diluted to 4 µg/ml each were added to microtiter plates and incubated overnight at 4°C. They were then washed with a phosphate buffer solution and subjected to a blocking procedure by addition of phosphate buffer solution containing 1% BSA. After adding 100 µl of the reaction solution and 100 µl of the specimen thereto and mixing, the reaction was carried out at room temperature for 1.5 hours. After removing the unreacted materials by washing with a phosphate buffer solution containing a low concentration of detergent, monoclonal antibodies C11-10 and C11-14 labeled with alkali phosphatase were added for reaction at room temperature for 30 minutes. After completion of the reaction, the unreacted materials was removed by washing with a phosphate buffer solution containing a low concentration of detergents, and a substrate solution (CDP-Star/emerald11) was added for reaction at room temperature for 15 minutes, after which the luminescence was measured.

Different detergents were added to the primary reaction solution and their effects were examined. HCV antigen-positive serum with an anti-HCV antibody titer below the detection level and thought to contain virtually no anti-HCV antibody was used, and the core antigen detection sensitivities were determined based on the degree of luminescence and expressed as reaction ratios relative to 1.0 as the luminescence for healthy human serum. The results are shown in the following

Tables 2 and 3.

Table 2

Reaction ratio (S/N ratio) for each serum with respect to healthy human serum						
	No.45	No.46	No.3	No.7	No.19	
Not added	15.67	1.00	1.15	1.34	1.19	
Effect judgment criterion	>30.0	>2.0	>2.0	>2.0	>2.0	>2.0
Additive	HLB value	%				
Anionic detergent	sodium dodecyl sulfate	40.0	0.5	5.42		
	sodium dodecyl-N-sarcosinate	0.5	5.73			
	perfluoroalkylic acid S-113 (ASAHI GLASS)	2.0	125.43	2.70		
Cationic detergent	cetyltrimethylammonium bromide	0.5	10.55	7.27		
	dodecylpyridinium chloride	2.0	6.72	1.27		
	n-dodecyltrimethylammonium	0.5	66.84	0.91		
	tetradecylammonium bromide	2.0	27.98	4.43		
	n-octyltrimethylammonium chloride	0.5	14.69	2.49		
Non-ionic detergent	CHAPS	2.0	11.46	3.77		
	perfluoroalkylbetaine S-132 (ASAHI GLASS)	0.5	29.57	4.49		
	3-(dodecyldimethylammonio)-1-propanesulfonic acid	2.0	113.19	1.61		
		2.0	113.19	1.49	1.63	2.67
		2.0	113.19	4.57	3.44	5.26

Table 3

Reaction ratio (S/N ratio) for each serum with respect to healthy human serum							
	No. 45	No. 46	No. 3	No. 7	No. 19		
<b>Not added</b>	15.67	1.00	1.15	1.34	1.19		
<b>Effect judgment criterion</b>	>30.0	>2.0	>2.0	>2.0	>2.0		
<b>Additive</b>	HLB value	%					
<b>Non-ionic detergent</b>							
MEGA-10	0.5	32.11	3.38				
Tween 20	2.0	38.49	3.53	1.97	1.87	2.84	
Tween 40	0.5	16.88					
Tween 80	2.0	12.36					
Nonidet P-40	0.5	14.96					
Octyl glycoside	0.5	19.10					
Triton N101	0.5	12.45					
Triton X100	0.5	17.47					
Triton X114	0.5	43.14					
Triton X305	0.5	12.48					
Triton X405	0.5	25.07					
Others							
benzyldimethylphenylammonium chloride	0.5	31.49	5.45	1.00			
triethylamine	2.0	58.62	7.01	1.12			
Detergent mixture	0.5	10.50	3.89	0.97			
2% sodium dodecyl-N-sarcosinate + 2%		244.13					
Triton X100			6.11	5.50	12.71		

These results demonstrated that addition of non-ionic detergents exhibiting HLB values of 12 to 14, as represented by Triton X100, increased the luminescence and raised the detection sensitivity in HCV antigen-positive serum with respect to healthy human serum. It was also demonstrated that addition of detergents with both linear alkyl chains and secondary to quaternary amines in their structures, as represented by sodium dodecyl-N-sarcosinate and dodecyltrimethylammonium, also raised the detection sensitivity in HCV antigen-positive serum. No such sensitivity-raising effect was found with the surfactants having alkyl groups of 8 or fewer carbon atoms. Addition of a mixture of these two types of surfactants (mixture of 2% sodium dodecyl-N-sarcosinate + 2% Triton X100 in Table 2) was also shown to raise the detection sensitivity in HCV antigen-positive serum.

Example 5. Core antigen detection in specimens after HCV infection and before HCV antibody appearance  
(during window period)

A commercially available PHV905 seroconversion panel (BBI Inc.) was measured according to Example 4 with addition of 2% Triton X100 and 2% sodium dodecyl-N-sarcosinate to the reaction solution. The PHV905 panel used here exhibited positive conversion in the anti-HCV antibody test (Ortho EIA. 3.0) on the 21st day after initial observation (Serum No.PHV905-7), the antibody titer being represented by the cutoff index (S/CO), with 1.0 or greater judged as positive. The HCV core antigen activity (luminescence) was represented as a ratio (S/N) with respect to 1.0 as the luminescence for healthy human serum.

As shown in Table 4, core antigen activity was found even before anti-HCV antibody positivity, thus confirming that addition of the surfactant resulted in exposure of the core antigen from the viral particles, thus allowing its reaction with the immobilized monoclonal antibodies

and its detection.

Table 4

Serum No.	Days after initial observation	HCV core antigen activity (S/N)	Anti-HCV antibody titer (S/CO)
PHV 905-1	0	5.32	0.000
905-2	4	8.30	0.000
905-3	7	15.63	0.000
905-4	11	4.37	0.300
905-5	14	14.75	0.700
905-6	18	7.57	0.700
905-7	21	4.82	2.500
905-8	25	3.31	5.000
905-9	28	1.61	5.000

5

Example 6. Simultaneous detection of HCV antibody and core antigen in specimen

A specimen (human serum) was used which contained an antibody for an HCV epitope but virtually no HCV antigen, and the following method was used to confirm that it was possible for the antibody for the HCV epitope to bind with the HCV polypeptide in the primary reaction solution containing the detergent without inactivation and for it to be detected by addition of anti-human antibody in a secondary reaction solution, and to confirm that it was possible to detect the core antigen when the core antigen was present, the antibody when the antibody for the HCV epitope was present, and both when both were present.

The EIA was performed basically under the following conditions. Recombinant antigen CEPM containing an HCV epitope was diluted in a urea-containing phosphate buffer solution, and then added to a microtiter plate and incubated overnight at 4°C. After washing with a phosphate buffer solution, a solution prepared by diluting monoclonal antibodies C11-3 and C11-7 in an

20

15

25

acetate buffer solution was added to the plate and  
incubated overnight at 4°C. The method of preparing the  
recombinant antigen CEPM is described in Japanese Patent  
Application No. 9-209522. After removal of the antibody  
5 solution, it was washed with a phosphate buffer solution  
and subjected to a blocking procedure by addition of a  
phosphate buffer solution containing 1% BSA.

After adding 100 µl of a primary reaction solution  
containing Triton X100, sodium dodecyl-N-sarcosinate and  
10 urea and 100 µl of the specimen in that order and  
stirring, the reaction was carried out at room  
temperature for 1.5 hours. After removing the unreacted  
matter by washing with a phosphate buffer solution  
containing a low concentration of added surfactant, a  
15 secondary reaction solution containing the anti-HCV core  
antigen monoclonal antibody C11-14 labeled with  
horseradish peroxidase and anti-human IgG mouse  
monoclonal antibody was added for reaction at room  
temperature for 30 minutes.

20 After completion of the reaction, the unreacted  
matter was removed by washing with a phosphate buffer  
solution containing a low concentration of added  
surfactant, and a substrate solution (ortho-  
phenylenediamine) was added for reaction at room  
25 temperature for 20 minutes, after which the luminescence  
was measured.

HCV antibody-positive human serum which had been  
confirmed to contain virtually no HCV core antigen was  
diluted with horse serum and used for specimens to  
30 confirm detection of antibodies for the HCV epitope, by  
which it was found to react in a concentration-dependent  
manner and the antibody was confirmed to be detected  
without inactivation in the primary reaction solution.

Table 5 Simultaneous measurement of HCV antigen and HCV antibody

Labeled antibody:		(Comp. Ex.)	(Comp. Ex.)	(Invention)
		POD-labeled c11-14	POD-labeled anti-human IgG	POD-labeled c11-14 and POD-labeled anti-human IgG
Solid phase		c11-3 and c11-7	CEPM	c11-3 and c11-7 and CEPN
Sample				
Recombinant core antigen ng/ml	Positive serum dilution degree			
-	-	0.001	0.000	0.000
50	-	2.784	0.000	2.834
12.5	-	2.822	0.000	2.758
3.1	x2048	1.586	0.210	1.341
0.78	x512	0.423	0.539	0.815
0.2	x128	0.085	1.139	1.151
0.048	x32	0.014	1.746	1.621
-	x8	0.000	2.161	1.824

(Values: OD492/OD690)

5

Separately, a recombinant core antigen was added to horse serum and diluted with horse serum for use as specimens, which were measured to confirm that the recombinant core antigen could be detected in a concentration-dependent manner.

10

When specimens containing appropriate amounts of added core antigen and human serum were used as specimens, a signal for the recombinant core antigen was obtained when only the recombinant core antigen was present, a signal for only the HCV antibody was obtained when only the human HCV antibody-positive serum was present, and a summated signal of both signals was obtained when both were present, as shown in Table 4. It was thus shown that both the antigen detection system and the antibody detection system functioned properly without interfering with each other, thus allowing detection of the HCV antigen and the antibody for the HCV polypeptide epitope.

15

20

Example 7. Antigen-antibody assay method for human serum

A healthy human specimen, a patient specimen and a serum positive-conversion panel specimen (BBI, Inc.) were used for simultaneous measurement of antigen and antibody according to the method described in Example 6. The panel serum was used for comparison with the results determined using a vending agency-supplied HCV antibody detection reagent.

The results of measurement of 18 healthy human specimens are shown in Table 6, and confirm that no reaction occurred in the healthy persons. Based on the distribution for the healthy persons, the critical value between positivity and negativity was determined to be 0.1.

Positive values were exhibited for all of the HCV-positive specimens, as shown in Table 7.

However, as shown in Table 8, the points 1 to 6 for which positivity could not be determined in antibody testing of the panel sera were given positive judgments. These points were given positive judgments in the results of the Amplicor HCV test, and correspond to the window period, and therefore positivity was also confirmed with the window period specimens.

DRAFT - FOR OFFICIAL USE ONLY

Table 6

Specimen No.	Absorption
Healthy human 1	0.063
2	0.057
3	0.066
4	0.025
5	0.045
6	0.063
7	0.047
10	0.033
11	0.036
13	0.037
14	0.030
15	0.028
16	0.031
17	0.040
18	0.051
19	0.052
20	0.031
21	0.053
mean	0.044

5

Table 7

Patient specimens	Absorption
3	2.892 positive
16	2.335 positive
45	0.394 positive
84	2.769 positive

10

Table 8

Panel sera	Absorption	Judgment	Antibody assay	Amplicor HCV test
PHV907-1	0.557	positive	negative	positive
2	0.397	positive	negative	positive
3	0.357	positive	negative	positive
4	0.224	positive	negative	positive
5	0.192	positive	negative	positive
6	0.247	positive	positive	positive
7	2.414	positive	positive	positive

Example 8. Preparation of monoclonal antibody

According to the method described in Example 3, another hybridoma was constructed and designated as HC11-5 15. This hybridoma was deposited at the National Institute of Bioscience and Human Technology on July 16, 1999 as FERM BP-9782. Monoclonal antibody produced by 10 this hybridoma was purified and its isotype was identified as IgG1. As a result of an epitope analysis using 20 peptides synthesized on the basis of the sequence of core region, said monoclonal antibody was found to specifically recognize  $^{15}\text{Thr}$ - $^{30}\text{Ile}$  (SEQ ID NO:9).

Example 9. Determination of antibody titer of the monoclonal antibody

15 The recombinant core antigen (Trp C11) was diluted in 10 mM phosphate buffer (pH 7.3) containing 6M urea to a final concentration of 2  $\mu\text{g}/\text{ml}$ , and 100  $\mu\text{l}$  of the solution was added to each well of a microplate. After allowing to stand at 4°C overnight, the solution was 20 aspirated off, and the wells were washed twice with 10 mM phosphate buffer (pH 7.3). 350  $\mu\text{l}$  of 10 mM phosphate buffer (pH 7.3) containing 0.5% casein was added to each well, and after incubation at room temperature for an hour, the buffer was aspirated off. Each monoclonal 25 antibody (C11-3, C11-7, C11-10, C11-14 or C11-15) sequentially diluted with a reaction mixture was added to each well, and reacted for an hour. After washing, a peroxidase-labeled anti-mouse antibody was added, reacted for 30 minutes, and after washing, an enzyme reaction was 30 carried out by adding a substrate solution comprising orthophenylenediamine and hydrogen peroxide. After reaction at room temperature for 30 minutes, 2N sulfuric acid was added to terminate the enzyme reaction, and absorbance at 492 nm was measured by a microplate reader.

35 The C11-15 exhibited the highest antibody titer, revealing that if this antibody is used as a secondary antigen, detection with a high sensitivity can be

obtained.

Example 10. Sandwich ELISA using different immobilized monoclonal antibodies

Monoclonal antibody (C11-3, C11-5, and C11-15; C11-3 and C11-7; C11-3 and C11-15; C11-3 alone; C11-7 alone; or C11-15 alone) was diluted in 10 mM phosphate buffer (pH 7.3) to a final concentration of 6 µg/ml, and 100 µl of the solution was added to each well of microplate. After allowing to stand at 4°C overnight, the buffer was aspirated off, and the wells were washed twice with 10 mM phosphate buffer (pH 7.3). 350 µl of 10 mM phosphate buffer (pH 7.3) containing 0.5% casein was added, and after incubation at room temperature for two hours, the buffer was aspirated off. 100 µl of a specimen which is HCV-RNA positive and anti-HCV antibody negative and 100 µl of a reaction solution were added to each well, and reacted at room temperature for an hour. After washing, a peroxidase-labeled anti-core antigen monoclonal antibody (a mixture of C11-14 and C11-10) was added, and reacted for 30 minutes, and after washing, an enzyme reaction was carried out by adding a substrate solution comprising orthophenylenediamine and hydrogen peroxide. After reaction at room temperature for 30 minutes, 2N sulfuric acid was added to terminate the enzyme reaction, and the absorbance at 292 nm was measured by a microplate reader. A result is shown in Fig. 2.

It was revealed that although detection sensitivity is low if only C11-15 was immobilized, the detection sensitivity increases by immobilizing a mixture of C11-15, and C11-3 or C11-7 etc.

Example 11. Expression and purification of epitope-chimeric antigen

*E. coli* transformant CEPM/HB101 was cultured in an LB medium containing 100 µg/ml ampicillin at 37°C overnight. The culture was inoculated to M9-CA containing 100 µg/ml ampicillin by an inoculum size of 1% concentration, and cultured at 37°C overnight. After

finishing the culturing, the microbial cells were collected by centrifugation, and resuspended in 50 ml of a lysis solution [50 mM Tris-HCl (pH 8.5), 30 mM NaCl, 5 mM EDTA], and after adding 1 ml of a lysozyme solution (10 mg/ml Lysozyme), were inoculated at 37°C for an hour. This suspension was subjected to ultrasonication (150W, 90 seconds, twice) so as to disrupt the cells. An insoluble fraction was recovered by centrifugation at 15000 rpm, 4°C for 30 minutes. The insoluble fraction was resuspended in 50 ml of A solution [50 mM Tris-HCl (pH 8.5)] containing 1% NP40, and homogenated (1500 rpm, 5 strokes). The suspension was centrifuged at 1500 rpm, 4°C for 30 minutes to recover an insoluble fraction. The insoluble fraction was resuspended in 50 ml of the A solution containing 2M urea, and homogenized (1500 rpm, 5 strokes). The suspension was centrifuged at 15000 rpm, 4°C for 30 minutes to recover an insoluble fraction. The insoluble fraction was resuspended in 50 ml of the solution A containing 6M urea, and homogenized (1500 rpm, 5 strokes). The suspension was centrifuged at 15000 rpm, 4°C for 30 minutes to recover a soluble fraction.

The epitope chimeric antigen was purified from the antigen solution prepared by solubilization with 6M urea-containing solution, by an ion exchange using S Sepharose HP column (Pharmacia) and gel-filtration using Superdex 75 pg (Pharmacia).

Note that an nucleotide sequence of DNA encoding said chimeric antigen is shown in SEQ ID NO:10, and the amino acid sequence of the chimeric antigen is shown in SEQ ID NO:11.

Reference to Microorganisms deposited under Rule 13-2 of PCT and Depository Institute  
Depository Institute

Name: The National Institute of Bioscience and Human  
Technology

Address: 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki,  
Japan

Microorganisms

- (1) Identification: HC11-3  
Deposition No: FERM BP-6002  
Deposition date: July 4, 1997
- 5 (2) Identification: HC11-7  
Deposition No: FERM BP-6003  
Deposition date: July 4, 1997
- 10 (3) Identification: HC11-10  
Deposition No: FERM BP-6004  
Deposition date: July 4, 1997
- (4) Identification: HC11-11  
Deposition No: FERM BP-6005  
Deposition date: July 4, 1997
- 15 (5) Identification: HC11-4  
Deposition No: FERM BP-6006  
Deposition date: July 4, 1997
- (6) Identification: HC11-15  
Deposition No: FERM BP-6782  
Deposition date: July 16, 1999

CLAIMS


1. A method for measurement of the hepatitis C virus (HCV), characterized by measuring HCV core antigen by its binding with one or more probes in the presence of 5 one or more detergents with one or more alkyl chains of at least 10 carbon atoms and one or more secondary to quaternary amines, or one or more non-ionic surfactants, or both.
- 10 2. A method according to claim 1, wherein said detergent with an alkyl chain and a secondary to quaternary amine is a surfactant with an alkyl group of 12 to 16 carbon atoms and a tertiary or quaternary amine.
- 15 3. A method according to claim 1 or 2, wherein said tertiary or quaternary amine detergent is dodecyl-N-sarcosinic acid, a cetyl or dodecyl trimethylammonium salt, 3-(dodecyldimethylammonio)-1-propanesulfonic acid, a dodecylpyrimidium salt or decanoyl-N-methylglucamide (MEGA-10).
- 20 4. A method according to any one of claims 1 to 3, wherein said non-ionic detergent is a surfactant with a hydrophilic-lipophilic balance (HLB) of 12 to 14.
- 25 5. A method according to any one of claims 1 to 4, wherein said non-ionic detergent is polyoxyethylene isoctylphenyl ether or polyoxyethylene nonylphenyl ether.
- 30 6. A method for measurement of the hepatitis C virus (HCV), characterized by measuring HCV core antigen by a method according to claims 1 to 5 while also measuring anti-HCV antibodies by its binding with probes.
7. A method according to claim 6, wherein the probe for said anti-HCV antibody is an HCV-related polypeptide.

ABSTRACT

A method for measurement of the hepatitis C virus (HCV) characterized by measuring HCV core antigen and HCV core antibody by their binding with probes in the presence of an anionic surfactant or a non-ionic surfactant, or both.


09/509449

Fig.1



09/509449

Fig. 2



**Declaration and Power of Attorney For Patent Application**

特許出願宣言書及び委任状

**Japanese Language Declaration**

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者であると（下記の名称が複数の場合）信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHOD FOR MEASUREMENT OF HEPATITIS C VIRUS

上記発明の明細書（下記の欄で×印がついていない場合は、本書に添付）は、

the specification of which is attached hereto unless the following box is checked:

was filed on July 30, 1999  
 as United States Application Number or  
 PCT International Application Number  
PCT/JP99/04129 and was amended on  
 \_\_\_\_\_ (if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されるおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

## Japanese Language Declaration (日本語宣言書)

私は、米国法典第35編119条(a)-(d)項又は365条(b)項に基づき下記の、米国以外の国の少なくとも一ヵ国を指定している特許協力条約365条(a)項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

**Prior Foreign Application(s)**

外国での先行出願

10-216094 (Pat. Appln.)	Japan
(Number) (番号)	(Country) (国名)
_____	_____
(Number) (番号)	(Country) (国名)

私は、第35編米国法典119条(e)項に基いて下記の米国特許出願規定に記載された権利をここに主張いたします。

(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------

私は、下記の米国法典第35編120条に基いて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約365条(c)に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願書提出日以降で本出願書の日本国内または特許協力条約国提出までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------

(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------

私は、私自身の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じるところに基づく表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の声明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

**Priority Not Claimed**

優先権主張なし

30/July/1998	<input type="checkbox"/>
(Day/Month/Year Filed) (出願年月日)	

(Day/Month/Year Filed) (出願年月日)	<input type="checkbox"/>
-----------------------------------	--------------------------

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Status: Patented, Pending, Abandoned) (現況: 特許可済、係属中、放棄済)	
--	--

(Status: Patented, Pending, Abandoned) (現況: 特許可済、係属中、放棄済)	
--	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following attorney(s) and/or patent agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith:

Albrecht, John W.	Reg. No. 40,481	Lacy, Paul E.	Reg. No. 38,946
Anderson, Gregg I!	Reg. No. 28,828	Larson, James A.	Reg. No. 40,443
Ansems, Gregory M.	Reg. No. 42,264	Lasky, Michael B.	Reg. No. 29,555
Batzli, Brian H.	Reg. No. 32,960	Liepa, Mara E.	Reg. No. 40,066
Beard, John L.	Reg. No. 27,612	Lindquist, Timothy A.	Reg. No. 40,701
Black, Bruce E.	Reg. No. 41,622	Lynch, David W.	Reg. No. 36,204
Blasdell, Thomas L.	Reg. No. 31,329	Marschang, Diane L.	Reg. No. 35,600
Bogucki, Raymond A.	Reg. No. 17,426	McDaniel, Karen D.	Reg. No. 37,674
Bruess, Steven C.	Reg. No. 34,130	McDonald, Daniel W.	Reg. No. 32,044
Byrne, Linda M.	Reg. No. 32,404	McIntyre, Iain A.	Reg. No. 40,337
Carlson, Alan G.	Reg. No. 25,959	Mueller, Douglas P.	Reg. No. 30,300
Caspers, Philip P.	Reg. No. 33,227	Nelson, Albin J.	Reg. No. 28,650
Chiapetta, James R.	Reg. No. 39,634	Pauly, Daniel M.	Reg. No. 40,123
Clifford, John A.	Reg. No. 30,247	Phillips, John B.	Reg. No. 37,206
Cochran, William W.	Reg. No. 26,652	Plunkett, Theodore	Reg. No. 37,209
Daignault, Ronald A.	Reg. No. 25,968	Pytel, Melissa J.	Reg. No. 41,512
Daley, Dennis R.	Reg. No. 34,994	Reich, John C.	Reg. No. 37,703
Dalglish, Leslie E.	Reg. No. 40,579	Reiland, Earl D.	Reg. No. 25,767
Daulton, Julie R.	Reg. No. 36,414	Rittmaster, Ted R.	Reg. No. 32,933
DeVries Smith, Katherine M.	Reg. No. 42,157	Schmaltz, David G.	Reg. No. 39,828
DiPietro, Mark J.	Reg. No. 28,707	Schuman, Mark D.	Reg. No. 31,197
Edell, Robert T.	Reg. No. 20,187	Schumann, Michael D.	Reg. No. 30,422
Epp Ryan, Sandra	Reg. No. 39,667	Scull, Timothy B.	Reg. No. 42,137
Funk, Steven R.	Reg. No. 37,830	Sebald, Gregory A.	Reg. No. 33,280
Glance, Robert J.	Reg. No. 40,620	Skoog, Mark T.	Reg. No. 40,178
Golla, Charles E.	Reg. No. 26,896	Soderberg, Richard	Reg. No. P-43,352
Gorman, Alan G.	Reg. No. 38,472	Sumner, John P.	Reg. No. 29,114
Gould, John D.	Reg. No. 18,223	Sumners, John S.	Reg. No. 24,216
Gregson, Richard	Reg. No. 41,804	Tellekson, David K.	Reg. No. 32,314
Gresens, John J.	Reg. No. 33,112	Trembath, Jon R.	Reg. No. 38,344
Hamre, Curtis B.	Reg. No. 29,165	Underhill, Albert L.	Reg. No. 27,403
Hillson, Randall A.	Reg. No. 31,838	Vandenburgh, J. Derek	Reg. No. 32,179
Holzer, Jr., Richard J.	Reg. No. 42,668	Vradenburgh, Anna M.	Reg. No. 39,868
Johnston, Scott W.	Reg. No. 39,721	Welter, Paul A.	Reg. No. 20,890
Kadievitch, Natalie D.	Reg. No. 34,196	Whipps, Brian	Reg. No. 43,261
Kastelic, Joseph M.	Reg. No. 37,160	Wickhem, J. Scot	Reg. No. 41,376
Kettelberger, Denise	Reg. No. 33,924	Williams, Douglas J.	Reg. No. 27,054
Knearl, Homer L.	Reg. No. 21,197	Witt, Jonelle	Reg. No. 41,980
Kowalczyk, Alan W.	Reg. No. 31,535	Wood, William J.	Reg. No. 42,236
Kowalczyk, Katherine M.	Reg. No. 36,848	Xu, Min S.	Reg. No. 39,536
Kubota, Glenn M.	Reg. No. 44,197		

I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct Merchant & Gould P.C. to the contrary.

Please direct all correspondence in this case to Merchant & Gould P.C. at the address indicated below:

Merchant & Gould P.C.  
3100 Norwest Center  
90 South Seventh Street  
Minneapolis, MN 55402-4131

## Japanese Language Declaration (日本語宣言書)

委任状： 私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。（弁護士、または代理人の氏名及び登録番号を明記のこと）

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number)  
Please see attached page

書類送付先

Send Correspondence to:

Curtis B. Hamre  
Merchant & Gould, P.C.  
90 South Seventh Street, Suite 3100  
Minneapolis, MN 55402 U.S.A.

直接電話連絡先：（名前及び電話番号）

Direct Telephone Calls to: (name and telephone number)

Curtis B. Hamre 612.336.4722

第一または第一発明者名		Full name of sole or first inventor	
		Katsumi Aoyagi	
発明者の署名	日付	Inventor's signature	Date
		Katsumi Aoyagi	March 17, 2000
住所		Residence	
		Wako-shi, Saitama, Japan	
国籍		Citizenship	
		Japanese	
私書箱		Post Office Address	
		c/o Advanced Life Science Institute, Inc.	
		2-10-23, Maruyamadai, Wako-shi, Saitama,	
		351-0112, Japan	
第二共同発明者		Full name of second joint inventor, if any	
		Chiharu Ohue	
第二共同発明者	日付	Second inventor's signature	Date
		Chiharu Ohue	March 17, 2000
住所		Residence	
		Wako-shi, Saitama, Japan	
国籍		Citizenship	
		Japanese	
私書箱		Post Office Address	
		c/o Advanced Life Science Institute, Inc.	
		2-10-23, Maruyamadai, Wako-shi, Saitama,	
		351-0112, Japan	

（第三以降の共同発明者についても同様に記載し、署名すること）

(Supply similar information and signature for third and subsequent joint inventors.)

第三共同発明者名		Full name of third joint inventor, if any Kumiko Iida	
第三共同発明者の署名	日付	Third inventor's signature <i>Kumiko Iida</i>	Date March 17, 2000
住所	Residence Wako-shi, Saitama, Japan		
国籍	Citizenship Japanese		
私書箱	Post Office Address c/o Advanced Life Science Institute, Inc., 2-10-23, Maruyamadai, Wako-shi, Saitama, 351-0112, Japan		
第四共同発明者名	Full name of fourth joint inventor, if any Shintaro Yagi		
第四共同発明者の署名	日付	Fourth inventor's signature <i>Shintaro Yagi</i>	Date March 17, 2000
住所	Residence Wako-shi, Saitama, Japan		
国籍	Citizenship Japanese		
私書箱	Post Office Address c/o Advanced Life Science Institute, Inc., 2-10-23, Maruyamadai, Wako-shi, Saitama, 351-0112, Japan		
第五共同発明者名	Full name of fifth joint inventor, if any		
第五共同発明者の署名	日付	Fifth inventor's signature	Date
住所	Residence		
国籍	Citizenship		
私書箱	Post Office Address		
第六共同発明者名	Full name of sixth joint inventor, if any		
第六共同発明者の署名	日付	Sixth inventor's signature	Date
住所	Residence		
国籍	Citizenship		
私書箱	Post Office Address		

09/509449  
416 Rec'd PCT/PTO 28 MAR 2000

S/N unknown

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant:	AOYAGI, et al.	Docket No.:	594.352USWO
Serial No.:	Unknown	Filed:	concurrent herewith
Int'l Appln No.:	PCTJP9904129	Int'l Filing Date:	July 30, 1999
Title:	METHOD FOR MEASUREMENT OF HEPATITIS C VIRUS		

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EL 415888455US

Date of Deposit: March 28, 2000

I hereby certify that this correspondence is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By:   
Name: Linda McCormick

SUBMISSION OF SEQUENCE LISTING

BOX PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231


Dear Sir:

Applicant's enclose herewith a computer readable form and paper copy of the Sequence Listing in accordance with the requirements of 37 C.F.R. 1.821 – 1.825. Applicants hereby state that the computer readable form and the paper copy of the Sequence Listing are the same and include no new matter.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, MN 55402-0903  
(612) 332-5300

Dated: March 28, 2000

By   
Curtis B. Hamre  
Reg No. 29,165  
CBH:jjw

09/509449

416 Rec'd PCT/PTO 28 MAR 2000

SEQUENCE LISTING

<110> Tonen Corporation

<120> Method for Measurement of hepatitis C virus

<130> G902

<150> JP-10-216094

<151> 1998-07-30

<160> 9

<210> 1

<211> 177

<212> PRT

<213> Hepatitis virus

<400> 1

Met Lys Ala Ile Phe Val Leu Lys Gly Ser Leu Asp Arg Asp Pro Glu

1 5 10 15

Phe Met Gly Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr

20 25 30

Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile Val

35 40 45

Gly Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg

50 55 60

Ala Thr Arg Lys Thr Ser Lys Arg Ser Gln Pro Arg Gly Arg Arg

65 70 75 80

Pro Ile Pro Lys Asp Arg Arg Ser Thr Gly Lys Ser Trp Gly Lys Pro

85 90 95

Gly Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly

100 105 110

Trp Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp

115 120 125

Pro Arg His Arg Ser Arg Asn Val Gly Lys Val Ile Asp Thr Leu Thr  
130 135 140

Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Phe Arg Val Gly Ala Phe  
145 150 155 160

Leu Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu  
165 170 175

Asp

<210> 2

<211> 160

<212> PRT

<213> Hepatitis virus

<400> 2

Met Gly Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn  
1 5 10 15

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile Val Gly  
20 25 30

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala  
35 40 45

Thr Arg Lys Thr Ser Lys Arg Ser Gln Pro Arg Gly Gly Arg Arg Pro  
50 55 60

Ile Pro Lys Asp Arg Arg Ser Thr Gly Lys Ser Trp Gly Lys Pro Gly  
65 70 75 80

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp  
85 90 95

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro  
100 105 110

Arg His Arg Ser Arg Asn Val Gly Lys Val Ile Asp Thr Leu Thr Cys  
115 120 125

Gly Phe Ala Asp Leu Met Gly Tyr Ile Phe Arg Val Gly Ala Phe Leu  
130 135 140

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp  
145 150 155 160

<210> 3

<211> 20

<212> PRT  
<213> Artificial Sequence

<220>  
<223>

<400> 3  
Asp Val Lys Phe Pro Gly Gly Gln Ile Val Gly Gly Val Tyr Leu  
1 5 10 15  
Leu Pro Arg Arg  
20

<210> 4  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223>

<400> 4  
Gly Pro Arg Leu Gly Val Arg Ala Thr Arg  
1 5 10

<210> 5  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223>

<400> 5  
Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro Arg His Arg  
1 5 10 15

Ser Arg Asn Val Gly

20

<210> 6

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<230>

<400> 6

Asp Pro Arg His Arg Ser Arg Asn Val Gly Lys Val Lle Asp Thr Leu  
1 5 10 15

Thr Cys Gly Phe

20

<210> 7

<211> 24

<212> DNA

<213> Artificial Sequence

<220> Probe

<230> Synthetic DNA

<400> 7

gaattcattgg gcacgaatcc taaa

24

<210> 8

<211> 21

<212> DNA

<213> Artificial Sequence

<220> Probe

DRAFT GENOME SEQUENCING

<230> Synthetic DNA

<400> 8

ttagtcctcc agaaccggaa c

21

<210> 9

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<230>

<400> 9

Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile  
1 5 10 15

<210> 10

<211> 1197

<212> DNA

<213> Artificial Sequence

<220>

<230> Nucleotide sequence coding for chimeric antigen

<400> 10

gaa ttc acc aaa gtg ccg gtt gct tat gcg gcc aaa ggt tat aag gtc 48  
Glu Phe Thr Lys Val Pro Val Ala Tyr Ala Ala Lys Gly Tyr Lys Val  
5 10 15

ctg gtt ctg gac ccg agc gtt gcc agc acc ctg ggt ttc ggc gcg tat 96  
Leu Val Leu Asp Pro Ser Val Ala Ser Thr Leu Gly Phe Gly Ala Tyr  
20 25 30

ctg agc aag gcc cat ggt gtg aac ccg aac atc cgc acg ggc atc cgt 144

Leu Ser Lys Ala His Gly Val Asn Pro Asn Ile Arg Thr Gly Ile Arg			
35	40	45	
acc gtt acc acc ggt gct ccg gtg acc tat tcc acc tac ggt aaa tac			192
Thr Val Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Tyr			
50	55	60	
ctg gcg gac ggc ggt tgc gcc ggc ggt gcg tac gat gtg atc gga tct			240
Leu Ala Asp Gly Gly Cys Ala Gly Gly Ala Tyr Asp Val Ile Gly Ser			
65	70	75	80
gga gag gag gtg gcc ctg tct aac act gga gag gtc ccc ttc tat ggc			288
Gly Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Val Pro Phe Tyr Gly			
85	90	95	
cgc gcg atc ccg atc gaa gcg atc aaa ggc ggt cgc cat ctg gtt ttc			336
Arg Ala Ile Pro Ile Glu Ala Ile Lys Gly Gly Arg His Leu Val Phe			
100	105	110	
tgc cat agc aag gag aaa tgc gat gaa ctg gcg agc gcg ctg tcc gga			384
Cys His Ser Lys Glu Lys Cys Asp Glu Leu Ala Ser Ala Leu Ser Gly			
115	120	125	
ttg ggt ctg aac gct gtg gca ttc tat cgc ggt ctg gac gtg agc att			432
Leu Gly Leu Asn Ala Val Ala Phe Tyr Arg Gly Leu Asp Val Ser Ile			
130	135	140	
atc ccg acc cag ggc gat gtg gtt atc gtt agc acc gat gcg ctg atg			480
Ile Pro Thr Gln Gly Asp Val Val Ile Val Ser Thr Asp Ala Leu Met			
145	150	155	160
acc ggt ttt acc ggc gat ttt gac tca gtg gtc gac tgt aac aca tgc			528
Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Val Asp Cys Asn Thr Cys			
165	170	175	
atc acc cag gga tct gga ctg gta agc ttc gcg agc cat gtg ccg tac			576
Ile Thr Gln Gly Ser Gly Leu Val Ser Phe Ala Ser His Val Pro Tyr			
180	185	190	
atc gag cag ggt atg caa ctg agc gaa caa ttt aag cag aag agc ctg			624
Ile Glu Gln Gly Met Gln Leu Ser Glu Gln Phe Lys Gln Lys Ser Leu			
195	200	205	
ggt ctg ctg cag acc gcg acc aaa cag gcg gag gcg gcc gcc ccg gtg			672
Gly Leu Leu Gln Thr Ala Thr Lys Gln Ala Glu Ala Ala Ala Pro Val			
210	215	220	
gtt ggc acc ccg aaa agc cgc cgt ccg gaa ggt cgt gcc tgg gcg caa			720

Val	Gly	Thr	Pro	Lys	Ser	Arg	Arg	Pro	Glu	Gly	Arg	Ala	Trp	Ala	Gln	
225																240
ccg	ggt	acc	atc	atc	ctg	agc	ggt	cgt	ccg	gcg	gtt	gta	ccg	gat	cgt	768
Pro	Gly	Thr	Ile	Ile	Leu	Ser	Gly	Arg	Pro	Ala	Val	Val	Pro	Asp	Arg	
																245
gaa	gtg	ctg	tat	caa	gaa	ttt	ctc	gag	gcc	tct	aga	gcg	gct	ctc	att	816
Glu	Val	Leu	Tyr	Gln	Glu	Phe	Leu	Glu	Ala	Ser	Arg	Ala	Ala	Leu	Ile	
																260
gaa	gag	ggg	caa	cg	ata	gcc	gag	atg	ctg	aag	tcc	aag	atc	cag	ggc	864
Glu	Glu	Gly	Gln	Arg	Ile	Ala	Glu	Met	Leu	Lys	Ser	Lys	Ile	Gln	Gly	
																275
tta	ctg	cag	caa	gcc	tcc	aag	cag	gcc	caa	gac	ata	aaa	atc	gac	gg	912
Leu	Leu	Gln	Gln	Ala	Ser	Lys	Gln	Ala	Gln	Asp	Ile	Lys	Ile	Asp	Gly	
																290
acc	ctg	att	att	ccg	aaa	gat	cgt	cgc	agc	acc	gg	aaa	agc	tgg	gg	960
Thr	Leu	Ile	Ile	Pro	Lys	Asp	Arg	Arg	Ser	Thr	Gly	Lys	Ser	Trp	Gly	
																305
aaa	ccg	ggc	ttc	ctc	atc	gat	agc	ttg	cat	atc	aac	cag	cga	gcc	gtc	1008
Lys	Pro	Gly	Phe	Leu	Ile	Asp	Ser	Leu	His	Ile	Asn	Gln	Arg	Ala	Val	
																325
gtt	gca	ccg	gac	aag	gag	gtc	ttt	tat	gag	gct	ttt	gat	gag	atg	gag	1056
Val	Ala	Pro	Asp	Lys	Glu	Val	Leu	Tyr	Glu	Ala	Phe	Asp	Glu	Met	Glu	
																340
ctc	gcc	atg	ggc	acc	aac	ccg	aaa	ccg	gag	cgt	aaa	agc	aag	cgt	aac	1104
Leu	Ala	Met	Gly	Thr	Asn	Pro	Lys	Pro	Glu	Arg	Lys	Ser	Lys	Arg	Asn	
																355
acc	aac	cgt	aaa	ccg	cag	gat	att	aaa	ttc	ccg	gg	agt	gg	cag	gt	1152
Thr	Asn	Arg	Lys	Pro	Gln	Asp	Ile	Lys	Phe	Pro	Gly	Ser	Gly	Gln	Val	
																370
gtg	gg	gg	gt	tac	ctg	gt	ccg	cgt	cgt	gg	ccg	taaggatcc				1197
Val	Gly	Gly	Val	Tyr	Leu	Val	Pro	Arg	Arg	Gly	Pro					
																385
																390
																395
<210>		11														
<211>		396														
<212>		PRT														
<213>		Artificial Sequence														

<220>

<230> Amino acid sequence of chimeric antigen

<400> 11

Glu Phe Thr Lys Val Pro Val Ala Tyr Ala Ala Lys Gly Tyr Lys Val  
5 10 15  
Leu Val Leu Asp Pro Ser Val Ala Ser Thr Leu Gly Phe Gly Ala Tyr  
20 25 30  
Leu Ser Lys Ala His Gly Val Asn Pro Asn Ile Arg Thr Gly Ile Arg  
35 40 45  
Thr Val Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Tyr  
50 55 60  
Leu Ala Asp Gly Gly Cys Ala Gly Ala Tyr Asp Val Ile Gly Ser  
65 70 75 80  
Gly Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Val Pro Phe Tyr Gly  
85 90 95  
Arg Ala Ile Pro Ile Glu Ala Ile Lys Gly Gly Arg His Leu Val Phe  
100 105 110  
Cys His Ser Lys Glu Lys Cys Asp Glu Leu Ala Ser Ala Leu Ser Gly  
115 120 125  
Leu Gly Leu Asn Ala Val Ala Phe Tyr Arg Gly Leu Asp Val Ser Ile  
130 135 140  
Ile Pro Thr Gln Gly Asp Val Val Ile Val Ser Thr Asp Ala Leu Met  
145 150 155 160  
Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Val Asp Cys Asn Thr Cys  
165 170 175  
Ile Thr Gln Gly Ser Gly Leu Val Ser Phe Ala Ser His Val Pro Tyr  
180 185 190  
Ile Glu Gln Gly Met Gln Leu Ser Glu Gln Phe Lys Gln Lys Ser Leu  
195 200 205  
Gly Leu Leu Gln Thr Ala Thr Lys Gln Ala Glu Ala Ala Ala Pro Val  
210 215 220  
Val Gly Thr Pro Lys Ser Arg Arg Pro Glu Gly Arg Ala Trp Ala Gln  
225 230 235 240

Pro Gly Thr Ile Ile Leu Ser Gly Arg Pro Ala Val Val Pro Asp Arg  
245 250 255  
Glu Val Leu Tyr Gln Glu Phe Leu Glu Ala Ser Arg Ala Ala Leu Ile  
260 265 270  
Glu Glu Gly Gln Arg Ile Ala Glu Met Leu Lys Ser Lys Ile Gln Gly  
275 280 285  
Leu Leu Gln Gln Ala Ser Lys Gln Ala Gln Asp Ile Lys Ile Asp Gly  
290 295 300  
Thr Leu Ile Ile Pro Lys Asp Arg Arg Ser Thr Gly Lys Ser Trp Gly  
305 310 315 320  
Lys Pro Gly Phe Leu Ile Asp Ser Leu His Ile Asn Gln Arg Ala Val  
325 330 335  
Val Ala Pro Asp Lys Glu Val Leu Tyr Glu Ala Phe Asp Glu Met Glu  
340 345 350  
Leu Ala Met Gly Thr Asn Pro Lys Pro Glu Arg Lys Ser Lys Arg Asn  
355 360 365  
Thr Asn Arg Lys Pro Gln Asp Ile Lys Phe Pro Gly Ser Gly Gln Val  
370 375 380  
Val Gly Gly Val Tyr Leu Val Pro Arg Arg Gly Pro  
385 390 395